Skip to main content
SpringerLink
Log in
Book cover

Hodgkin Lymphoma pp 203–209Cite as

Relapsed and Refractory Hodgkin Lymphoma

  • Chapter
  • First Online:

Part of the book series: Hematologic Malignancies ((HEMATOLOGIC))

Abstract

Hodgkin lymphoma (HL) is a commonly cured malignancy. Unfortunately, patients who are refractory to or relapse after first-line treatment pose a significant therapeutic challenge. There is evidence that these patients are best treated with salvage chemotherapy followed by high-dose chemotherapy and autologous stem cell transplant (HDCT/ASCT). This approach cures 40–60% of patients. Outcome is better in patients with low-risk relapse; relapsed patients with poor prognostic scores or those with refractory disease have a poorer prognosis. More aggressive transplant approaches have given promising results in the latter group and are currently under active investigation. For those patients relapsing after HDCT/ASCT, a range of therapeutic options is being offered including other salvage chemotherapy, reduced-intensity allogeneic transplantation, monoclonal antibodies, and novel agents. Generally, patients with relapsed HL should be enrolled in clinical trials.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   199.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Josting A, Wolf J, Diehl V. Hodgkin’s disease. Prognostic factors and treatment strategies. Curr Opin Oncol. 2000;12:403–11.

    Article  PubMed  CAS  Google Scholar 

  2. Fisher R, De VV, Hubbard S, et al. Prolonged disease-free survival in Hodgkin disease with MOPP reinduction after first relapse. Ann Intern Med. 1979;90:761–5.

    PubMed  CAS  Google Scholar 

  3. Longo D, Duffey P, Young R, et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin disease after combination chemotherapy: the low probability for cure. J Clin Oncol. 1992;10:210–8.

    PubMed  CAS  Google Scholar 

  4. Bonfante V, Santoro A, Viviani S, et al. Outcome of patients with Hodgkin disease failing after primary MOPP/ABVD. J Clin Oncol. 1997;15:528–34.

    PubMed  CAS  Google Scholar 

  5. Josting A, Rueffer U, Franklin J, et al. Prognostic factors and treatment outcome in primary progressive Hodgkin’s lymphoma – a report from the German Hodgkin’s Lymphoma Study Group (GHSG). Blood. 2000;96(4):1280–6.

    PubMed  CAS  Google Scholar 

  6. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin disease: a randomised trial. Lancet. 2002;359(9323):2065–71.

    Article  PubMed  CAS  Google Scholar 

  7. Lohri A, Barnett M, Fairey RN, et al. Outcome of treatment of first relapse of Hodgkin disease after primary chemotherapy: identification of risk factors from the British Columbia experience 1970 to 1988. Blood. 1991;77(10):2292–8.

    PubMed  CAS  Google Scholar 

  8. Fermè C, Bastion Y, Lepage E, et al. The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin disease. Ann Oncol. 1995;6(6):543–9.

    PubMed  Google Scholar 

  9. Reece D, Barnett M, Shepherd J, et al. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/− P) and autologous transplantation for patients with Hodgkin disease who fail to enter a complete remission after combination chemotherapy. Blood. 1995;86:451–8.

    PubMed  CAS  Google Scholar 

  10. Brice P, Bastion Y, Divine M, et al. Analysis of prognostic factors after the first relapse of Hodgkin disease in 187 patients. Cancer. 1996;78(6):1293–9.

    Article  PubMed  CAS  Google Scholar 

  11. Josting A, Franklin J, May M, et al. A new prognostic score based on treatment outcome of patients with relapsed Hodgkin lymphoma registered in the database of the German Hodgkin Lymphoma Study Group (GHSG). J Clin Oncol. 2002;20(1):221–30.

    Article  PubMed  Google Scholar 

  12. Cannellos G, Young RC, De Vita VD. Combination chemotherapy for advanced Hodgkin’s disease in relapse following extensive radiotherapy. Clin Pharm Ther. 1972;13:750–8.

    CAS  Google Scholar 

  13. Santoro A, Viviani S, Villarreal C, et al. Salvage chemotherapy in Hodgkin disease irradiation failures: superiority of doxorubicin-containing regimens over MOPP. Cancer Treat Rep. 1986;70:343–51.

    PubMed  CAS  Google Scholar 

  14. Josting A, Katay I, Rueffer U, et al. Favorable outcome of patients with relapsed or refractory Hodgkin disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dexa-BEAM). Ann Oncol. 1998;9:289–96.

    Article  PubMed  CAS  Google Scholar 

  15. Biermann PJ, Bagin RG, Jagannath S, et al. High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin’s disease: long term follow-up in 128 patients. Ann Oncol. 1993;4:767–73.

    Google Scholar 

  16. Reece DE, Connors JM, Spinelli JJ, et al. Intensive therapy with cyclophosphamide, carmustine, etoposide +/− cisplatin, and autologous bone marrow transplantation for Hodgkin’s disease in first relapse after combination chemotherapy. Blood. 1994;83(5):1193–9.

    PubMed  CAS  Google Scholar 

  17. Armitage JO, Biermann PJ, Vose JM, et al. Autologous bone marrow transplantation for patients with relapsed Hodgkin’s disease. Am J Med. 1991;91:605–10.

    Article  PubMed  CAS  Google Scholar 

  18. Linch D, Winfield D, Goldstone A, et al. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin disease: results of a BNLI randomised trial. Lancet. 1993;341:1051–4.

    Article  PubMed  CAS  Google Scholar 

  19. Gianni AM, Siena S, Bregni M, Lombardi F, et al. High-dose sequential chemo-radiotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin’s disease – a 6-year update. Ann Oncol. 1993;4:889–91.

    PubMed  CAS  Google Scholar 

  20. Gianni AM, Bregni M, Siena S. 5-year update of the Milan Cancer Institute randomized trial of high-dose sequential (HDS) vs MACOP-B therapy for diffuse large-cell lymphomas. Proc ASCO. 1994;13:373 (A1263).

    Google Scholar 

  21. Patrone F, Ballestrero A, Ferrando F, Brema F, Moraglio L, Valbonesi M, et al. Four-step high-dose sequential chemotherapy with double hematopoetic progenitor-cell rescue for metastatic breast cancer. J Clin Oncol. 1995;13:840–6.

    PubMed  CAS  Google Scholar 

  22. Shea T, Mason JR, Storniolo AM, et al. Sequential cycles of high-dose carboplatin administered with recombinat human granulocyte-makrophage colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: a novel and effective method for delivering multiple courses of dose-intensive therapy. J Clin Oncol. 1992;10:464–73.

    PubMed  CAS  Google Scholar 

  23. Gianni AM, Taella C, Bregni M, et al. High-dose sequential chemo-radiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma. J Clin Oncol. 1994;12:503–9.

    PubMed  CAS  Google Scholar 

  24. Caracciolo D, Gavarotti P, Aglietta M, et al. High-dose sequential chemotherapy with blood and marrow cell autograft as salvage treatment in very poor prognosis, relapsed non-Hodgkin’s lymphoma. Bone Marrow Transplant. 1993;12:621–5.

    PubMed  CAS  Google Scholar 

  25. Norton L, Simon R. The Norton-Simon hypothesis revisited. Canc Treat Rep. 1986;70:163–9.

    CAS  Google Scholar 

  26. Josting A, Rudolph C, Mapara M, et al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma – results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Blood. 2003;102(11 Suppl 1):1461.

    Google Scholar 

  27. Anderson JE, Litzow MR, Appelbaum FR, et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin’s disease: the 21-year Seattle experience. J Clin Oncol. 1993;11:2342–50.

    PubMed  CAS  Google Scholar 

  28. Phillips GL, Reece DE, Barnett MJ, et al. Allogeneic marrow transplantation for refractory Hodgkin’s disease. J Clin Oncol. 1989;7:1039–45.

    PubMed  CAS  Google Scholar 

  29. Jones RJ, Piantadosi S, Mann RB, et al. High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin’s disease. J Clin Oncol. 1990;8:527–37.

    PubMed  CAS  Google Scholar 

  30. Milpied N, Fielding AK, Pearce RM, et al. Allogeneic bone marrow transplantation is not better than autologous transplant for patients with relapsed Hodgkin’s disease. J Clin Oncol. 1996;14:1291–6.

    PubMed  CAS  Google Scholar 

  31. Carella AM, Cavaliere M, Beltrami G, et al. Immunosuppressive nonmyeloablative allografting as salvage therapy in advanced Hodgkin disease. Haematologica. 2001;86(11):1121–3.

    PubMed  CAS  Google Scholar 

  32. Sureda A, Robinson S, Canals C, et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2008;26(3):455–62.

    Article  PubMed  CAS  Google Scholar 

  33. Schmitz N, Sureda A, Robinson S. Allogeneic transplantation of hematopoietic stem cells after nonmyeloablative conditioning for Hodgkin disease: indications and results. Semin Oncol. 2004;31(1):27–32.

    Article  PubMed  Google Scholar 

  34. Devizzi L, Santaro A, Bonfante V, et al. Vinorelbine: an active drug for the management of patients with heavily pretreated Hodgkin’s disease. Ann Oncol. 1994;5:817–20.

    PubMed  CAS  Google Scholar 

  35. Santoro A, Bredenfeld H, Devizzi L, et al. Gemcitabine in the treatment of refractory Hodgkin disease: results of a multicenter phase II study. J Clin Oncol. 2000;18:2615–9.

    PubMed  CAS  Google Scholar 

  36. Engert A, Diehl V, Schnell R, et al. A phase I study of an anti-CD25 ricin A chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin’s lymphoma. Blood. 1997;15:403–10.

    Google Scholar 

  37. Schnell R, Stark O, Borchmann P, et al. A phase I study with an anti-CD30 ricin A-chain Immunotoxin (Ki-4.dgA) in patients with refractory CD30 positive Hodgkins and non-Hodgkin’s lymphoma. Clin Canc Res. 2002;8(6):1779–86.

    CAS  Google Scholar 

  38. Hartmann F, Renner C, Jung W, et al. Treatment of refractory Hodgkin’s disease with an anti-CD16/CD30 bispecific antibody. Blood. 1997;15:2042–7.

    Google Scholar 

  39. Borchmann P, Schnell R, Fuss I, et al. Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma. Blood. 2002;100:3101–7.

    Article  PubMed  CAS  Google Scholar 

  40. Younes A, Romaguera J, Hagemeister F, et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer. 2003;98(2):310–4.

    Article  PubMed  CAS  Google Scholar 

  41. Borchmann P, Morschhauser F, Parry A, et al. The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma. Blood. 2003;102(10):3737–3742.

    Article  PubMed  CAS  Google Scholar 

  42. Reiners KS, Gossmann A, von Strandmann EP, et al. Effects of the anti-VEGF monoclonal antibody bevacizumab in a preclinical model and in patients with refractory and multiple relapsed Hodgkin lymphoma. J Immunother. 2009;32(5):508–12.

    Article  PubMed  CAS  Google Scholar 

  43. Evens A, et al. Phase I analysis of the safety and pharmacodynamics of the Novel Broad Spectrum Histone Deacetylase Inhibitor PCI-24781 in relapsed and refractory lymphoma. Blood. 2009;114(22):2726A.

    Google Scholar 

  44. Younes A, et al Personal communication (August 2010).

    Google Scholar 

  45. Younes A, et al. Novel targeted therapy for relapsed Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2009;1:507–19.

    Google Scholar 

  46. Crocchiolo R, Canevari C, Assanelli A, et al. Pre-transplant 18FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantation. Leuk Lymphoma. 2008;49(4):727–33.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. German Hodgkin Lymphoma Study Group (GHSG), Gleueler Str. 269–271, 50935, Köln, Germany

    Andreas Josting

  2. 984455 Nebraska Medical Ctr., Omaha, NE, 68198–4455, USA

    Philip J. Biermann

Authors
  1. Andreas Josting
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Philip J. Biermann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andreas Josting .

Editor information

Editors and Affiliations

  1. Klinik I für Innere Medizin, Universität Köln, Joseph-Stelzmann-Str. 9, Köln, 50924, Germany

    Andreas Engert

  2. Dept. Medicine, Stanford University, Stanford, 94305-5479, California, USA

    Sandra J. Horning

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Josting, A., Biermann, P.J. (2011). Relapsed and Refractory Hodgkin Lymphoma. In: Engert, A., Horning, S. (eds) Hodgkin Lymphoma. Hematologic Malignancies. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-12780-9_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-12780-9_13

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-12779-3

  • Online ISBN: 978-3-642-12780-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation